Propylhexedrine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:464217507
Drug Name:Propylhexedrine
Iupac Name:(±)-1-cyclohexyl-N-methylpropan-2-amine
Imagel:Propylhex_3d.png
Imager:Propylhex_3d (R).png
Captionlr:Left: (S)-Propylhexedrine
Right: (R)-Propylhexedrine
Tradename:Benzedrex, Obesin, Dristan Inhaler, and others
Pregnancy Category:C
Legal Au:S4
Legal Br:B1
Legal Ca:Unscheduled
Legal De:Prescription Only
Legal Us:OTC
Legal Un:Unscheduled
Legal Uk:P
Routes Of Administration:Medical: Intranasal (inhaler)
Recreational: Oral and parenteral routes
Elimination Half-Life:4 ± 1.5 hours
Index2 Label:hydrochloride
Cas Number:101-40-6
Cas Number2:1007-33-6
Atc Prefix:N06BA
Pubchem:7558
Drugbank:DB06714
Chemspiderid:7277
Unii:LQU92IU8LL
Unii2:064LUN7NZ5
Kegg:D05637
C:10
H:21
N:1
Smiles:N(C(CC1CCCCC1)C)C
Stdinchi:1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3
Stdinchikey:JCRIVQIOJSSCQD-UHFFFAOYSA-N
Chirality:Racemic mixture

Propylhexedrine, commonly sold under the brand name Benzedrex, is an alkylamine primarily utilized as a topical nasal decongestant.[1] Its main indications are relief of congestion due to colds, allergies, and allergic rhinitis.[2] Propylhexedrine was first used medically in 1949, with the release of Benzedrex by Smith, Kline & French, and it has been used, mainly within the United States, since then.

Medical use

Propylhexedrine is used to treat acute nasal congestion related to the common cold, allergies and hay fever. For nasal congestion, the dosage is listed as four inhalations (two inhalations per nostril) every two hours for adults and children 6–12 years of age. Each inhalation delivers 0.4 to 0.5 milligrams (400 to 500 μg) in 800 millilitres of air. Use is not to exceed three days.

Historically, it has also been used for weight loss in oral tablet preparations at a dose of 25 milligrams.[3] No medications containing propylhexedrine are currently approved for weight loss in any country since roughly 1976.

Contraindications

Propylhexedrine should not be used if a MAOI has been used in the past 14 days or is currently in use by a person.

Unlike other topical decongestants, propylhexedrine is not required to carry a warning against use in individuals with hypertension.[4]

Propylhexedrine is not recommended in individuals younger than six years of age.[5] There is at least one case of reported accidental poisoning resulting from child access to a propylhexedrine product.

Adverse effects

When used as an inhaler, the most common adverse effects warned about for propylhexedrine are temporary discomfort (e.g., stinging or burning sensations) or rebound congestion. The sharing of propylhexedrine inhalers may spread infection. The occurrence of these adverse effects is uncommon as propylhexedrine is generally recognized as safe and effective.[6] However, the use of propylhexedrine products in manners not intended by their labeling can result in severe adverse effects not typically encountered in therapeutic settings. The outcomes of improperly using propylhexedrine products can include hospitalization, disability, or even death. Public health agencies such as the FDA have advised propylhexedrine products only be used in the manners directed on their label.

Overdose

Reports of overdoses from propylhexedrine have been documented, but they are uncommon. Most instances of overdoses attributed to propylhexedrine have been the result of improper use of a propylhexedrine product in a manner not intended by its labeling for (non-medical) recreational purposes.[7] As noted by the FDA, the most common symptoms of propylhexedrine overdose are the following: "...[R]apid heart rate, agitation, high blood pressure, chest pain, tremor, hallucinations, delusions, confusion, nausea, and vomiting." The use of propylhexedrine products in manners inconsistent with their labeling has proven fatal in some cases.[8] Propylhexedrine products are considered to be safe and effective if used as intended. Regardless, medical attention should be sought in the case of suspected overdose.

Interactions

Most of propylhexedrine's interactions with other medications have to do with its ability to constrict blood vessels. Propylhexedrine’s most serious interaction is with monoamine oxidase inhibitors, which are contraindicated. Monoamine oxidase inhibitors are used, albeit uncommonly, as an antidepressant.[9] Nonetheless, caution should be exercised when administering propylhexedrine concurrently with other medicines.

Pharmacology

Mechanism of action

Propylhexedrine works mainly as an adrenergic agonist, when used at therapeutic doses in an inhaler dosage form.[10] This restricts the blood vessels in the nose and reduces swelling; thereby, it relieves nasal congestion.[11] At higher doses, propylhexedrine affects the central nervous system as a norepinephrine–dopamine releasing agent. Propylhexedrine likely exerts such effects in a manner similar to related alkylamines such as cyclopentamine, methylhexanamine, and tuaminoheptane.[12] [13] [14] In addition, propylhexedrine further releases monoamines through TAAR1 agonism and VMAT2 inhibition. Propylhexedrine also exhibits antihypotensive effects.[15]

Pharmacokinetics

Propylhexedrine undergoes metabolism via N-demethylation, C-oxidation, N-oxidation, dehydrogenation, and hydrolysis to form various metabolites such as norpropylhexedrine, cyclohexylacetoxime, cyclohexylacetone, and 4-hydroxypropylhexedrine.[16]

Chemistry

Freebase propylhexedrine is a volatile, oily liquid at room temperature. The slow evaporation of freebase propylhexedrine allows it to be administered via inhalation.[17] The evaporation of the freebase also accounts for the limited shelf-life of propylhexedrine inhalers. Many of the salts of propylhexedrine are stable, clear to off-white crystalline substances that readily dissolve in water.[18]

Propylhexedrine is similar in chemical structure to phenylethylamines. Phenylethylamines and substituted phenethylamines are found in the core of many trace amines and sympathomimetic drugs. The main difference is the presence of an alicyclic cyclohexyl group instead of the aromatic phenyl group of a phenethylamine.

Propylhexedrine is a chiral compound. The active ingredient contained in Benzedrex inhalers is racemic (RS)-propylhexedrine as the free base. (S)-Propylhexedrine, also known as levopropylhexedrine, is believed to be the more biologically active isomer of the two. The dextrorotatory counterpart, which is mainly unused, is dextropropylhexedrine.

Synthesis

Propylhexedrine can be synthesized from cyclohexylacetone through the reductive amination of an intermediary imine over an aluminum-mercury amalgam in the presence of a hydrogen source.[19]

However, propylhexedrine is more commonly prepared by the catalytic hydrogenation of methamphetamine over Adams' catalyst. This transforms methamphetamine's phenyl ring to a cyclohexyl moiety.[20]

Detection in bodily fluids

Due to its structure, administration of propylhexedrine can lead to false positives for phenethylamine derivatives on urinalysis panels.[21] Propylhexedrine can be differentiated upon further analysis.[22]

History

Propylhexedrine's medical use as a decongestant evolved from desires to find safer alternatives to previous agents.[23] After searching for such an agent, Dr. Glenn E. Ullyot patented propylhexedrine as a decongestant in 1948. This patent was issued for benefit of Smith, Kline & French.[24] Before it was sold nationally in the United States, propylhexedrine underwent market trials in California. These market trials began on July 15, 1949. Propylhexedrine (under the brand name Benzedrex) was first introduced into interstate commerce on August 4, 1949.[25] Approval for use in the United Kingdom soon followed in 1956. Later, approval for use in Canada was granted in 1998.[26] In 2023, B. F. Ascher & Co. decreased the amount of propylhexedrine in the Benzedrex inhaler from its historic 250 milligrams down to 175 milligrams.[27]

Barbexaclone, an anticonvulsant containing propylhexedrine, was used in Turkey until its withdrawal from the market in 2009. Barbexaclone's former niche in Turkish medicine is now largely occupied by levetiracetam.[28]

Manufacturing

The manufacture of propylhexedrine products for therapeutic use is typically performed based on guidelines established in government regulations and pharmacopeia monographs.[29] [30]

The illicit manufacture or diversion of propylhexedrine by clandestine chemists for use as a recreational drug has been documented in academic literature. Similar to when opioids are manufactured clandestinely for recreational use, it is unlikely that propylhexedrine produced by clandestine chemists adheres to the standards for purity, identity, and strength required of therapeutic products.[31]

Society and culture

Legal status

International control

Propylhexedrine was placed under international control by the Convention on Psychotropic Substances in 1985. This action was reversed in 1991.[32]

Australia

Propylhexedrine is an S4 substance in Australia.[33]

Brazil

Propylhexedrine is a Class B1 substance in Brazil.[34]

Canada

Propylhexedrine was long reported to be a Schedule V substance in Canada.[35] In 2022, this status changed and propylhexedrine has since been removed from control under the Controlled Drugs and Substances Act.[36]

Germany

Propylhexedrine is regulated as a prescription medicine in Germany.[37] Initially, propylhexedrine products (namely Obesin) were available over-the-counter. However, this changed in the 1970s and propylhexedrine is now regulated as a prescription product in Germany.

United Kingdom

It was formerly a Class C substance in the United Kingdom, but was deregulated in 1995.[38] Propylhexedrine was used recreationally during a brief period in the 1970s after increased government regulation on earlier decongestants due to misuse.[39]

United States

On the 4th of April 1988, propylhexedrine was designated a controlled substance (Schedule V) in the United States.[40] This was done to satisfy U.S. compliance with an international treaty. However, in 1991, this action was reversed and propylhexedrine was removed from control under the Controlled Substances Act. This was based on the opinion of the Drug Enforcement Administration that propylhexedrine did not warrant control.[41] The substance has remained unregulated under the Controlled Substances Act in the United States ever since. Furthermore, pursuant to DEA regulations, certain Benzedrex inhalers are specifically exempt from the Controlled Substances Act.[42] [43] Propylhexedrine remains regulated under the laws of several U.S. states. These states include the states of Alaska,[44] Arizona,[45] Florida,[46] Georgia,[47] Idaho,[48] Kansas,[49] and Rhode Island.[50]

Recreational use

Multiple public health agencies (most notably within the United States) have warned against the recreational use of propylhexedrine and advised for its use only as directed by a product's labeling; nonetheless it has been reported, through the literature as early as 1959, that propylhexedrine products have been used for recreational purposes.[51] Recreational use is potentially fatal, its risks are magnified when administering the substance through injection means, and the adverse effects of recreational propylhexedrine are more severe when compared to related substances.[52] [53] The undesirable side effects of propylhexedrine at recreational doses are less tolerable compared to other substances that produce similar effects; consequently, propylhexedrine is less desirable for recreational use.[54] [55] [56] The fact that propylhexedrine is less potent than comparable substances has also limited recreational use.[57] [58] Even in areas with prevalent substance use, the use of propylhexedrine was reported as non-significant.[59] The recreational use of nasal decongestant,[60] anorectic, and anticonvulsant preparations[61] have all been reported. The recreational use of propylhexedrine products has been on the rise since the early 2000s.[62]

In 2021, the United States Food & Drug Administration issued the following warning in regard to recreational use of propylhexedrine products in manners inconsistent with their labeling:

That same year, the Indian Health Service issued the following statement[63] in reference to the recreational use of propylhexedrine products:

A year later, in 2022, the U.S. Army published the following guidance[64] on propylhexedrine. The guidance states that recreational use of propylhexedrine is not permissible by service-members, can open its participants up to disciplinary action, and carries potentially fatal risks:

Put briefly, the Food & Drug Administration, Indian Health Service, and U.S. Army all advise individuals not to use propylhexedrine products for recreational purposes.

Economics

Propylhexedrine, under the brand name Benzedrex, is sold online by retailers such as Amazon, eBay, and Walmart.[65] Propylhexedrine has been sold in some countries as an anorectic or as part of an anticonvulsant preparation; however, such products are not sold freely to consumers and require a physician's prescription.

Brand names

Benzedrex inhaler

Propylhexedrine, as a nasal decongestant, is currently marketed under the trade name Benzedrex. The name Benzedrex was initially trademarked by Smith, Kline & French in 1944.[66] The brand was passed onto Menley James Laboratories (through a subsidiary, NuMark Laboratories) in 1990, and was finally acquired by B. F. Ascher & Co. in 1998.[67] [68]

Dristan inhaler

Propylhexedrine was also sold in inhaler form by Whitehall Laboratories (Wyeth) under the Dristan brand name as an inhaler.[69] In January 1966, propylhexedrine replaced mephentermine as the active ingredient in the product.[70] The Dristan inhaler has since been discontinued. Furthermore, Wyeth was acquired by Pfizer in 2009. All products currently sold under the Dristan brand are manufactured by Foundation Consumer Brands; Foundation Consumer Brands acquired the Dristan brand in 2020.[71] Foundation Consumer Brands is itself owned by Kelso & Company.

Obesin

Propylhexedrine has also seen use in Europe as an appetite suppressant, under the trade name Obesin.[72] Obesin has been referenced in literature dating back to the 1950s.[73] Obesin was manufactured by Fahlberg-List in East Germany from 1958 to around 1976. The discontinuation of Obesin was the result of increased regulatory restrictions on over-the-counter anorectics. These restrictions began to be imposed in 1974.[74] Fahlberg-List itself dissolved in 1995.

Maliasin

Propylhexedrine is a component in the anticonvulsant preparation barbexaclone. Its S-isomer (levopropylhexedrine or L-propylhexedrine) is bonded with phenobarbital for the purpose of offsetting the barbiturate-induced sedation. Barbexaclone has been known under the brand name of Maliasin, manufactured by Abbott Laboratories, as early as 1965.[75] [76] Maliasin has also been manufactured by Knoll Pharmaceuticals; Knoll is a company acquired by Abbott Laboratories. In 2010, Abbott discontinued sale of its barbexaclone preparation in many countries.[77]

Eventin

Levopropylhexedrine (the more active optical isomer of propylhexedrine) has been used as an appetite suppressant under the brand name Eventin. Eventin's use has been documented as early as 1958.[78]

Notes and References

  1. Web site: June 7, 2023 . Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use . https://web.archive.org/web/20230706041627/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=341.20 . 6 July 2023 . July 5, 2023 . .
  2. Web site: BENZEDREX 09-19-2014- propylhexedrine inhalant . https://archive.today/20230716000914/https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03a8ef3c-a808-6208-e054-00144ff8d46c . July 16, 2023 . July 15, 2023 . Daily Med . U.S. National Library of Medicine.
  3. Docherty JR . Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) . British Journal of Pharmacology . 154 . 3 . 606–622 . June 2008 . 18500382 . 2439527 . 10.1038/bjp.2008.124 .
  4. Terrie YC . December 20, 2017 . Decongestants and Hypertension: Making Wise Choices When Selecting OTC Medications . live . https://web.archive.org/web/20230130120554/https://www.pharmacytimes.com/view/decongestants-and-hypertension-making-wise-choices-when-selecting-otc-medications . January 30, 2023 . November 13, 2023 . Pharmacy Times. December 2017 Heart Health . 83 .
  5. Web site: Propylhexedrine . https://archive.today/20230809073320/https://www.mskcc.org/cancer-care/patient-education/medications/adult/propylhexedrine . August 9, 2023 . 2023-07-16 . www.mskcc.org . Memorial Sloan Kettering Cancer Center . en.
  6. Web site: March 25, 2021 . Benzedrex (propylhexedrine): Drug Safety Communication . https://archive.today/20230807212835/https://www.fda.gov/safety/medical-product-safety-information/benzedrex-propylhexedrine-drug-safety-communication-fda-warns-abuse-and-misuse-nasal-decongestant . August 7, 2023 . July 16, 2023 . FDA.
  7. Web site: Center for Drug Evaluation and Research . 2021-04-15 . FDA warns that abuse and misuse of the nasal decongestant propylhexedrine causes serious harm . dead . https://web.archive.org/web/20230223010114/https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-abuse-and-misuse-nasal-decongestant-propylhexedrine-causes-serious-harm . 23 February 2023 . July 8, 2023 . . U.S. Food and Drug Administration . en.
  8. News: 1985-09-22 . Rise In Nasal Inhaler Abuse Worries Officials . en-US . 34 . . live . 2023-08-30 . https://archive.today/20230830042034/https://www.nytimes.com/1985/09/22/us/rise-in-nasal-inhaler-abuse-worries-officials.html . August 30, 2023 . 0362-4331.
  9. Web site: Monoamine oxidase inhibitors . 2024-05-15 . Mayo Clinic . en.
  10. Web site: Propylhexedrine . dead . https://web.archive.org/web/20120315115006/http://www.drugbank.ca/drugs/DB06714 . 15 March 2012 . July 8, 2023 . DrugBank.
  11. Web site: 2017-10-18 . Decongestants . https://archive.today/20230809064415/https://www.nhs.uk/conditions/decongestants/ . August 9, 2023 . 2023-08-09 . . en.
  12. Small C, Cheng MH, Belay SS, Bulloch SL, Zimmerman B, Sorkin A, Block ER . The Alkylamine Stimulant 1,3-Dimethylamylamine Exhibits Substrate-Like Regulation of Dopamine Transporter Function and Localization . The Journal of Pharmacology and Experimental Therapeutics . 386 . 2 . 266–273 . August 2023 . 37348963 . 10353075 . 10.1124/jpet.122.001573 .
  13. Schmidt JL, Fleming WW . A Nonsympathomimetic Effect of Cyclopentamine and Beta-Mercaptoethylamine in the Rabbit Ileum . The Journal of Pharmacology and Experimental Therapeutics . 145 . 83–86 . July 1964 . 14209515 .
  14. Delicado EG, Fideu MD, Miras-Portugal MT, Pourrias B, Aunis D . Effect of tuamine, heptaminol and two analogues on uptake and release of catecholamines in cultured chromaffin cells . Biochemical Pharmacology . 40 . 4 . 821–825 . August 1990 . 2386550 . 10.1016/0006-2952(90)90322-c .
  15. Lands AM, Nash VL . The pharmacologic activity of N-methyl-beta-cyclohexyl-isopropylamine hydrochloride . The Journal of Pharmacology and Experimental Therapeutics . 89 . 4 . 382–385 . April 1947 . 20295519 .
  16. Midha KK, Beckett AH, Saunders A . Identification of the major metabolites of propylhexedrine in vivo (in man) and in vitro (in guinea pig and rabbit) . Xenobiotica; the Fate of Foreign Compounds in Biological Systems . 4 . 10 . 627–635 . October 1974 . 4428789 . 10.1080/00498257409169765 .
  17. US. 4095596. Nasal Inhaler. granted. 20 June 1978. Grayson M . Smithkline Corp. .
  18. Mancusi-Ungaro HR, Decker WJ, Forshan VR, Blackwell SJ, Lewis SR . Tissue injuries associated with parenteral propylhexedrine abuse . Journal of Toxicology. Clinical Toxicology . 21 . 3 . 359–372 . 1983 . 6144800 . 10.1097/00005373-198307000-00114 .
  19. Book: Lednicer D, Mitscher LA . Organic Chemistry of Drug Synthesis . 1977 . Wiley . 978-0-471-52141-9 . 1 . New York, NY . 37.
  20. Zenitz BL, Macks EB, Moore ML . Preparation of some primary and secondary beta-cyclohexylalkylamines . Journal of the American Chemical Society . 69 . 5 . 1117–1121 . May 1947 . 20240502 . 10.1021/ja01197a039 .
  21. Thurman EM, Pedersen MJ, Stout RL, Martin T . Distinguishing sympathomimetic amines from amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry . Journal of Analytical Toxicology . 16 . 1 . 19–27 . 1992 . 1640694 . 10.1093/jat/16.1.19 .
  22. Johnson P, Briner RC . October 1992 . A Clandestine Laboratory Extracting Propylhexedrine from Benzedrex Inhalers . dead . Journal of the Clandestine Laboratory Investigating Chemists Association . 2 . 4 . 25–28 . https://web.archive.org/web/20230809075022/https://bitnest.netfirms.com/external/JCLIC/2.4.25-28 . 2023-08-09.
  23. Web site: Schwarez J . Sniffing Benzedrine Inhalers . dead . https://ghostarchive.org/archive/20230716000721/https://www.mcgill.ca/oss/article/medical-health-and-nutrition/sniffing-benzedrine-inhalers . 16 July 2023 . July 15, 2023 . Office for Science and Society . . en .
  24. US. 2454746A. Cyclohexylalkylamines. 1948-11-23. Ullyot GE . Smith Kline and French Laboratories Ltd. .
  25. Web site: Grant G . August 4, 1949 . Extension of remarks by representative Grant on H.R. 2969 - Bezedrine Inhalers . live . https://web.archive.org/web/20231029071225/https://www.govinfo.gov/content/pkg/GPO-CRECB-1949-pt15/pdf/GPO-CRECB-1949-pt15-1.pdf . October 29, 2023 . October 29, 2023 . . Volume 95 Issue 15 . . A5052 . .
  26. Web site: Propylhexedrine - NAPRA . https://archive.today/20230715190812/https://www.napra.ca/nds/propylhexedrine/ . July 15, 2023 . 2023-07-15 . (Canadian) National Association of Pharmacy Regulatory Authorities . en-US.
  27. Web site: BENZEDREX- propylhexedrine inhalant (06/23/2023) . live . https://archive.today/20231030224908/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00d8c237-3eee-1d9f-e063-6394a90aeb86 . October 30, 2023 . 2023-10-30 . Daily Med . U.S. National Library of Medicine.
  28. Bolukbasi F, Delil S, Bulus E, Senturk A, Yeni N, Karaagac N . End of the barbexaclone era: an experience of treatment withdrawal . Epileptic Disorders . 15 . 3 . 311–313 . September 2013 . 23981808 . 10.1684/epd.2013.0605 . 39112148 .
  29. Web site: September 9, 1976 . Federal Register Vol. 41, No. 176 . https://web.archive.org/web/20230716082330/https://www.govinfo.gov/content/pkg/FR-1976-09-09/pdf/FR-1976-09-09.pdf . July 16, 2023 . . 38402.
  30. Web site: USP Monographs: Propylhexedrine Inhalant . dead . https://web.archive.org/web/20231227063903/https://doi.usp.org/USPNF/USPNF_M71100_01_01.html . 27 December 2023 . 2023-12-27 . .
  31. Collier R . Street versions of opioids more potent and dangerous . CMAJ . 185 . 12 . 1027 . September 2013 . 23836854 . 3761004 . 10.1503/cmaj.109-4535 .
  32. Web site: September 28, 1990 . Expert Committee on Drug Dependence's Twenty-Seventh Report . live . https://web.archive.org/web/20230810175114/https://apps.who.int/iris/bitstream/handle/10665/40616/WHO_TRS_808.pdf?sequence=1&isAllowed=y . August 10, 2023 . July 3, 2023 . . Expert Committee on Drug Dependence.
  33. Web site: Therapeutic Goods (Poisons Standard—June 2024) . dead . https://archive.ph/JI6kV . August 13, 2024 . August 13, 2024 . Australian Government . en.
  34. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-03-31 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control . live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 2023-08-03 . 2023-08-16 . . pt-BR . 2023-04-04.
  35. Web site: Erowid Propylhexedrine (Benzedrex) Vault : Law . dead . https://web.archive.org/web/20230716004820/https://www.erowid.org/pharms/propylhexedrine/propylhexedrine_law.shtml . 16 July 2023 . 2023-07-15 . .
  36. Web site: Government of Canada . Public Works and Government Services Canada . 2022-08-31 . Canada Gazette, Part 2, Volume 156, Number 18: Order Amending Schedule V to the Controlled Drugs and Substances Act (Novel Fentanyl Precursors) . live . https://web.archive.org/web/20240331223724/https://www.gazette.gc.ca/rp-pr/p2/2022/2022-08-31/html/sor-dors185-eng.html . 2024-03-31 . 2024-03-31 . Canada Gazette.
  37. Web site: Anlage 1 AMVV - Einzelnorm . dead . https://archive.today/20151130183959/http://www.gesetze-im-internet.de/amvv/anlage_1.html . November 30, 2015 . 2023-07-16 . Bundestag.
  38. Web site: The Misuse of Drugs Act 1971 (Modification) Order 1995 . https://archive.today/20230807213717/https://www.legislation.gov.uk/uksi/1995/1966/article/2/made . August 7, 2023 . 15 June 2009 . Office of Public Sector Information.
  39. Web site: 2016-03-23 . The blanket drugs ban is necessary, but won't solve the bigger problem – as I know from personal experience . https://archive.today/20240430064109/http://theconversation.com/the-blanket-drugs-ban-is-necessary-but-wont-solve-the-bigger-problem-as-i-know-from-personal-experience-56237 . 2024-04-30 . 2023-11-19 . The Conversation . en-US . Wilson A.
  40. Web site: Lawn J . April 4, 1988 . Schedules of Controlled Substances: Placement of Propylhexedrine and Pyrovalerone into Schedule V . live . https://ghostarchive.org/archive/20221228191210/https://isomerdesign.com/Cdsa/FR/53FR10869.pdf . 28 December 2022 . 9 July 2022 . Isomer Design . .
  41. Web site: Bonner R . December 3, 1991 . Schedules of Controlled Substances: Removal of Propylhexedrine From Control . live . https://ghostarchive.org/archive/20221228191210/https://isomerdesign.com/Cdsa/FR/56FR61372.pdf . 28 December 2022 . 9 July 2022 . Isomer Design . .
  42. Web site: Sec. 1308.22 Excluded substances. . https://archive.today/20230531045652/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1308.22 . May 31, 2023 . May 30, 2023 . Code of Federal Regulations . Drug Enforcement Administration.
  43. Web site: Haislip G . January 11, 1989 . Excluded Non-narcotic Over-the-counter Substances . https://web.archive.org/web/20230627005235/https://archives.federalregister.gov/issue_slice/1989/1/19/2099-2101.pdf . June 27, 2023 . June 26, 2023 . . .
  44. Web site: 2014 Alaska Statutes :: Title 11 - Criminal Law :: Chapter 11.71 - Controlled Substances :: Article 02 - Standards and Schedules :: Sec. 11.71.180 Schedule VA. . https://archive.today/20231222072102/https://law.justia.com/codes/alaska/2014/title-11/chapter-11.71/article-02/section-11.71.180 . 2023-12-22 . 2023-12-22 . Justia Law . en.
  45. Web site: 2005 Arizona Revised Statutes - :: Revised Statutes §13-3401 Definitions . https://archive.today/20231222072833/https://law.justia.com/codes/arizona/2005/title13/03401.html . 2023-12-22 . 2023-12-22 . Justia Law . en.
  46. Web site: 2011 Florida Statutes :: TITLE XLVI — CRIMES :: Chapter 893 — Drug Abuse Prevention and Control :: 893.03 — Standards and schedules. . https://archive.today/20231222073123/https://law.justia.com/codes/florida/2011/titlexlvi/chapter893/section893.03 . 2023-12-22 . 2023-12-22 . Justia Law . en.
  47. Web site: 2022 Georgia Code :: Title 16 - Crimes and Offenses :: Chapter 13 - Controlled Substances :: Article 2 - Regulation of Controlled Substances :: Part 1 - Schedules, Offenses, and Penalties :: § 16-13-29.1. Nonnarcotic Substances Excluded From Schedules of Controlled Substances . https://archive.today/20231222073402/https://law.justia.com/codes/georgia/2022/title-16/chapter-13/article-2/part-1/section-16-13-29-1/ . 2023-12-22 . 2023-12-22 . Justia Law . en.
  48. Web site: 2010 Idaho Code :: Title 37 Food, Drugs, and Oil :: Chapter 27 Uniform Controlled Substances :: Article Ii :: 37-2713 Schedule V. . https://archive.today/20231222073801/https://law.justia.com/codes/idaho/2010/title37/t37ch27sect37-2713.html . 2023-12-22 . 2023-12-22 . Justia Law . en.
  49. Web site: 2017 Kansas Statutes :: Chapter 65 Public Health :: Article 41 Controlled Substances :: 65-4113 Substances included in schedule V. . https://archive.today/20231222074029/https://law.justia.com/codes/kansas/2017/chapter-65/article-41/section-65-4113/ . 2023-12-22 . 2023-12-22 . Justia Law . en.
  50. Web site: 2021 Rhode Island General Laws :: Title 21 - Food and Drugs :: Chapter 21-28 - Uniform Controlled Substances Act :: Section 21-28-2.08 - Contents of schedules. . https://archive.today/20231222074400/https://law.justia.com/codes/rhode-island/2021/title-21/chapter-21-28/section-21-28-2-08/ . 2023-12-22 . 2023-12-22 . Justia Law . en.
  51. Rose W . September 1959 . Arzneimittelsucht durch Mißbrauch von sogenannten Appetitzüglern (Obesin) . Archiv für Toxikologie . de . 17 . 5 . 331–335 . 10.1007/BF00577633 . 1959ArTox..17..331R . 1432-0738 . 31539217.
  52. Fornazzari L, Carlen PL, Kapur BM . Intravenous abuse of propylhexedrine (Benzedrex) and the risk of brainstem dysfunction in young adults . The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques . 13 . 4 . 337–339 . November 1986 . 2877725 . 10.1017/S0317167100036696 . free .
  53. Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J, Solomon CJ, Levine B . A drug toxicity death involving propylhexedrine and mitragynine . Journal of Analytical Toxicology . 35 . 1 . 54–59 . January 2011 . 21219704 . 10.1093/anatox/35.1.54 . free .
  54. Web site: Propylhexedrine (Benzedrex) . dead . https://ghostarchive.org/archive/20230716060703/https://www.poison.org/articles/propylhexedrine . 16 July 2023 . 2023-07-16 . National Capital Poison Control . en .
  55. Anderson ED . Propylhexedrine (Benzedrex) psychosis . The New Zealand Medical Journal . 71 . 456 . 302 . May 1970 . 5270979 . 30786926 .
  56. Sturner WQ, Spruill FG, Garriott JC . Two propylhexedrine-associated fatalities: Benzedrine revisited . Journal of Forensic Sciences . 19 . 3 . 572–574 . July 1974 . 4137337 . 10.1520/JFS10213J .
  57. Web site: Cooper D . "Future Synthetic Drugs of Abuse" . https://web.archive.org/web/20230809071331/https://www.erowid.org/library/books_online/future_synthetic/ . August 9, 2023 . 2023-08-09 . . .
  58. Garriott JC . Editorial: Propylhexadrine - a new dangerous drug? . Clinical Toxicology . 8 . 6 . 665–666 . 1975 . 6189 . 10.3109/15563657508990092 .
  59. Smith DE, Wesson DR, Sees KL, Morgan JP . An epidemiological and clinical analysis of propylhexedrine abuse in the United States . Journal of Psychoactive Drugs . 20 . 4 . 441–442 . 1988-10-01 . 2907528 . 10.1080/02791072.1988.10472514 .
  60. News: Curry B . September 5, 1985 . Abuse of Potentially Fatal Nasal Inhaler Medication by Injection Called Widespread . . September 7, 2023 . https://web.archive.org/web/20210509111800/https://www.latimes.com/archives/la-xpm-1985-09-05-mn-24755-story.html . May 9, 2021 .
  61. Darcın AE, Dilbaz N, Okay IT . Barbexaclone abuse in a cannabis ex-user . Substance Abuse . 31 . 4 . 270–272 . October 2010 . 21038181 . 10.1080/08897077.2010.514246 . 7076881 .
  62. Teja N, Dodge CP, Stanciu CN . Abuse, Toxicology and the Resurgence of Propylhexedrine: A Case Report and Review of Literature . Cureus . 12 . 10 . e10868 . October 2020 . 33178521 . 7652022 . 10.7759/cureus.10868 . free .
  63. Web site: 2021 . Abuse and Misuse of Propylhexedrine Nasal Decongestant Causes Serious Harm . https://web.archive.org/web/20230528203228/https://www.ihs.gov/nptc/pharmacovigilance/medication-safety-resources-archive/2021/abuse-and-misuse-of-propylhexedrine-nasal-decongestant-causes-serious-harm/ . May 28, 2023 . 2023-11-03 . National Pharmacy & Therapeutics Committee . . en.
  64. Web site: Parrish A . October 26, 2022 . FDA issues drug misuse guidance . https://web.archive.org/web/20221130001549/https://www.army.mil/article/261494/fda_issues_drug_misuse_guidance . November 30, 2022 . 2023-11-13 . . en.
  65. Web site: Benzedrex Inhaler . dead . https://web.archive.org/web/20230708192205/https://www.bfascher.com/products/benzedrex/ . 8 July 2023 . July 8, 2023 . B. F. Ascher and Company .
  66. Web site: Benzedrex Trademark of B.F. Ascher & Company Inc - Registration Number 0896775 - Serial Number 72340742 . dead . https://archive.today/20230716051433/https://trademarks.justia.com/723/40/benzedrex-72340742.html . July 16, 2023 . 2023-07-16 . Justia . en.
  67. Web site: Robertson V . February 17, 2004 . Prince v. B.F. Ascher Company, Inc., 90 P.3d 1020 (Okla. Civ. App. 2004) . live . https://ghostarchive.org/archive/20230716060731/https://casetext.com/case/prince-v-bf-ascher-company-inc . 16 July 2023 . 2023-07-16 . CaseText .
  68. Web site: March 1, 1999 . B.F. Ascher marks 50th year. . https://archive.today/20230809072522/https://www.thefreelibrary.com/B.F.+Ascher+marks+50th+year.-a054082926 . August 9, 2023 . 2023-08-09 . The Free Library . Chain Drug Review.
  69. Web site: November 24, 1989 . Action in Respect of International Conventions on Narcotic Drugs and Psychotropic Substances . https://web.archive.org/web/20231029070234/https://iris.who.int/bitstream/handle/10665/163484/EB85_23_eng.pdf?sequence=1 . October 29, 2023 . October 29, 2023 . .
  70. Angrist BM, Schweitzer JW, Gershon S, Friedhoff AJ . Mephentermine psychosis: misuse of the Wyamine inhaler . The American Journal of Psychiatry . 126 . 9 . 1315–1317 . March 1970 . 5413209 . 10.1176/ajp.126.9.1315 .
  71. Web site: October 1, 2020 . Foundation Consumer Healthcare to Add Seven Over-the-Counter Brands to Expanding Portfolio of Healthcare Products . https://web.archive.org/web/20231113224757/https://foundationch.com/assets/press-release/2020-10-01.pdf . November 13, 2023 . November 13, 2023 . Foundation Consumer Brands . Kelso & Company.
  72. Wesson DR . Propylhexdrine . Drug and Alcohol Dependence . 17 . 2–3 . 273–278 . June 1986 . 2874970 . 10.1016/0376-8716(86)90013-X .
  73. Polster H . Über eine Vergiftung mit dem Appetitzügler Propylhexedrin "Obesin", bei einem 3 Ährigen Kinde . About poisoning with the appetite suppressant propylhexedrine "Obesin" in a 3-year-old child . de . Archiv Fur Toxikologie . 20 . 271–273 . February 1965 . 5 . 14272412 . 10.1007/BF00577551 . 19812917 .
  74. Winter E . 1976 . Bemerkungen zu Drogenmißbrauch und -abhängigkeit vom Amphetamin- Typ unter besonderer Berücksichtigung des Amphetaminils (Aponeuron (R)) . Comments on amphetamine-type drug abuse and dependence with special reference to amphetaminil (Aponeuron) . Psychiatrie, Neurologie und medizinische Psychologie . DE . 28 . 9 . 513–525 . 45253962 . 0033-2739.
  75. Krueger HJ, Schwarz H . [Clinical Communication on the Therapy of Epilepsy With Maliasin] . Die Medizinische Welt . 14 . 690–692 . April 1965 . 14276849 .
  76. Web site: MALIASIN Trademark - Registration Number 0797076 - Serial Number 72213021 . dead . https://web.archive.org/web/20230716060838/https://trademarks.justia.com/722/13/maliasin-72213021.html . 16 July 2023 . 2023-07-16 . Justia . en .
  77. Web site: Serracchiani D . January 31, 2011 . Parliamentary question Maliasin P-001035/2011 European Parliament . dead . https://ghostarchive.org/archive/20230716050714/https://www.europarl.europa.eu/doceo/document/P-7-2011-001035_EN.html . 16 July 2023 . 2023-07-16 . . en .
  78. Hofer R, Locker A . [Therapeutic experiences with the appetite depressant eventin] ]. Wiener Medizinische Wochenschrift . 108 . 14 . 304–306 . April 1958 . 13558159 .